2 factor-β-activated kinase 1; TAB1, TAK1 binding protein; COX-2, cyclooxygenase-2; MMP-9, matrix metalloproteinase-9; TNF, tumor necrosis factor; TNFR, TNF receptor; TRADD, TNFR-associated death domain; TRAF2, TNFR-associated factor 2; NIK, NF-κB-inducing kinase; IAP, inhibitor-of-apoptosis protein; FBS, fetal bovine serum; SDS, sodium dodecyl sulfate; EMSA, electrophoretic mobility shift assay; VEGF, vascular endothelial growth factor; PMA, phorbol myristste kinase; LPS, lipopolysaccharide; HUVEC, Human umbilical vein endothelial cells. . A very limited information available on this flavone indicates that it exhibits potent antioxidant activity 3, 4 , suppresses b amyloid-induced toxicity 5 , mediates antinociception by modulating the g amino butyric acid system 6, 7 , protects against carbon tetrachloride-induced toxicity in rat hepatocytes 8 , and protects against bis(2-choloroethyl)sulfide-induced dermal toxicity 9 . Gossypin also has antiinflammatory activity as it prevented carrageenin-induced paw edema in mice by inhibiting arachidonic acid metabolism 10 .
Gossypin has been found to inhibit cell proliferation in L929, HT29, and K562 tumor cell lines in culture. In mice, it inhibited the growth of Ehrlich's ascites carcinoma and inhibited angiogenesis. It also exhibited anticarcinogenic activity against DMBA/croton oil-induced papilloma in rodents 4 . Gossypin's antitumoral effects have been partly ascribed to its ability to inhibit topoisomerase I and II 4 . However, the exact 5 mechanisms of its antiinflammatory and anticarcinogenic properties are not fully understood.
Nuclear factor-κB (NF-κB) is an inducible transcription factor for genes involved in cell survival, adhesion, inflammation, differentiation and growth. It regulates the genes that are critical in the early and late stages of aggressive cancers including cyclin D1, apoptosis-suppressor proteins such as Bcl-2 and Bcl-xL, and genes required for metastasis and angiogenesis, such as matrix metalloprotease (MMP) and vascular endothelial growth factor (VEGF) 11 .
Because NF-κB activation is common to both inflammation and cancer, we hypothesized that gossypin's antiinflammatory, anticarcinogenic, and antiangiogenic properties result from the inhibition of NF-κB and NF-κB-regulated gene expression.
Gossypin inhibited NF-κB activation induced by different agents, inhibited NF-κB-regulated gene expression, abrogated receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and VEGF induced migration of HUVEC. It also potentiated chemotherapeutic agents induced apoptosis.
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Materials and Methods
Reagents:
A 50 mM solution of gossypin and gossypetin (Sigma Aldrich, St. Louis, MO) was prepared in dimethyl sulfoxide; stored as small aliquots at -20°C and then thawed and diluted, as needed, in a cell culture medium. Bacteria-derived human recombinant TNF, purified to homogeneity with a specific activity of 5x10 7 
Electrophoretic mobility shift assay:
To determine NF-κB activation, we used electrophoretic mobility shift assays (EMSAs), as described previously 14 . In brief, nuclear extracts prepared from TNF-treated cells
were incubated with 32 P-end-labeled 45-mer double-stranded NF-κB oligonucleotide (15 8 µg protein with 16 fmol DNA) from the HIV long terminal repeat 5´'-TTGTTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGGCGTGG-3´ (boldface indicates NF-κB binding sites) for 30 min at 37°C. The DNA-protein complex that formed was separated from the free oligonucleotide on 6.6% native polyacrylamide gels. A double-stranded mutated oligonucleotide, 5´'-TTGTTACAACTCACTTTCCGCTGCTCACTTTCCAGGGAGGCGTGG-3', was used to evaluate the specificity of NF-κB binding to the DNA. The specificity was also determined through competition with the unlabeled oligonucleotide. The dried gels were visualized, and the radioactive bands were quantitated with a Storm 220
PhosphorImager (Amersham Biosciences, Piscataway, NJ) using ImageQuant software (Molecular Dynamics, Sunnyvale, CA)
Western blot analysis:
To determine the levels of protein expression in the cytoplasm and nucleus, we fractionated extracts with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), as described previously 15 . The proteins were then electrotransferred to nitrocellulose membranes, blotted with each antibody, and the expression of proteins were detected with an enhanced chemiluminescence reagent (Amersham Biosciences).
We quantitated the bands with National Institutes of Health imaging software (Bethesda, MD).
IKK assay:
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To determine the effects of gossypin on TNF-induced IKK activation, we used the IKK assay, as described previously 16 . In brief, to determine the total amounts of IKK-α and IKK-β in each sample, we resolved 50 µg whole-cell protein by 7.5% SDS-PAGE, electrotransferred it to a nitrocellulose membrane, and blotted it with anti-IKK-α or anti-IKK-β antibodies.
NF-κB -dependent reporter gene expression assay:
We performed an NF-κB -dependent reporter gene expression assay, as previously 
Immunocytochemical analysis of NF-κB p65 localization:
The effects of gossypin on p65 nuclear translocation were evaluated by an immunocytochemical analysis, as described previously 15 .
Live/Dead assay:
To determine membrane permeability, we used the Live/Dead assay (Molecular Probes, Eugene, OR), which measures intracellular esterase activity and plasma membrane integrity. This assay was performed as described previously 18 .
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Cytotoxicity assay:
The effects of gossypin on the cytotoxicity of TNF and chemotherapeutic agents were determined by the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide uptake method, as described previously 19 .
Annexin V assay:
An early indicator of apoptosis is the rapid translocation and accumulation of the Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay:
We also determined cytotoxicity using the terminal deoxynucleotidyl transferasemediated dUTP nick end labeling (TUNEL) method, which is used to evaluate DNA 11 strand breaks during apoptosis using an in situ cell death detection reagent. This assay was performed as described previously 20 .
Invasion assay:
Extracellular matrix invasion is a crucial step in tumor metastasis. Therefore, we determined the effect of gossypin with an invasion assay, as described previously 20 . A Matrigel basement membrane matrix extracted from the Engelbreth-Holm-Swarm mouse tumor (BD Biosciences) was reconstituted and used for this assay.
Osteoclast differentiation assay:
We performed an osteoclast differentiation assay, as described previously 21 . In brief, primary bone marrow cells from C57BL/6J mice (6 week old) were isolated as described 22 . These cells and RAW 264.7 cells were cultured in 24-well dishes at a density of 1x10 4 per well and allowed to adhere overnight. They were then exposed to RANKL, with or without gossypin, for different numbers of days and examined for osteoclast formation.
HUVEC Wound-Healing/ Migration Assay:
To determine the ability of gossypin to modulate the VEGF-induced HUVEC migration, wound-healing/ migration assay was performed 23 . 
Results
We evaluated the effects of gossypin on the NF-κB activation pathway, as induced by various carcinogens and inflammatory stimuli. We also determined its effects on NF-κB -regulated gene expression and NF-κB -mediated cellular responses. The TNF-induced NF-κB activation pathway has been well characterized. Moreover, TNF is the most potent proinflammatory cytokine and the most potent inducer of the NF-κB activation pathway. Thus, we determined gossypin's effects on TNF-induced NF-κB activation.
The structure of gossypin is shown in Fig. 1A . Previous studies have shown that the antioxidant activity of this flavonoid requires an o-dihydroxy structure in the B ring, C2, C3 double bonds in conjugation with the C4 keto group in the C ring, and C3, C5
OH groups with C4 oxo function 3 .
Gossypin inhibited NF-κB activation induced by various agents:
TNF, IL-1β, H 2 O 2 , PMA, LPS, okadaic acid, and cigarette smoke condensate are potent activators of NF-κB 12,15,24,25 ; thus, we determined gossypin's effects on NF-κB activation by these agents. All agents activated NF-κB in human KBM-5 cells, as determined by DNA binding assays, and incubation with gossypin suppressed this activation (Fig. 1B ).
Cells were fully viable at this concentration and exposure time. These results suggest that gossypin acts at a step in the NF-κB activation pathway that is common to all these agents.
Inhibition of NF-κB activation by gossypin was dose dependent:
14 TNF is one of the most potent activators of NF-κB, and the mechanism of NF-κB activation has been well established; thus, we determined gossypin's effects on TNFinduced NF-κB activation in myeloid leukemia (KBM-5) cells. Gossypin suppressed TNF-induced NF-κB activation in a dose-dependent manner (Fig. 1C) .
Suppression of NF-κB activation by gossypin was time dependent:
To determine the minimum time of exposure to gossypin required to inhibit TNFmediated NF-κB activation, cells were exposed to the inhibitor for 30 min or 1, 2, 4, or 8
h and then treated with TNF for 30 min. As shown in Figure 1D , gossypin had started to inhibit TNF-induced NF-κB activation after only 1 h. After 4 h, TNF-induced NF-κB activation was completely suppressed. Under these conditions, gossypin alone had no effect on NF-κB activation.
Inhibition of NF-κB activation by gossypin was specific and consisted of p50 and p65 subunits:
To determine the composition of the NF-κB band, nuclear extracts were incubated with anti-p50, anti-p65, unlabeled oligonucleotides, or mutated oligonucleotides. As shown in Figure 1E , both antibodies supershifted the band, indicating that the composition of the band was p50 and p65. Competition of the band with wild-type oligonucleotides but not mutant oligonucleotides showed that the band was specific.
Inhibition of NF-κB activation by gossypin was not cell type specific:
Because the signal transduction pathway mediated by NF-κB may be distinct in different cell types, we also determined whether gossypin blocked TNF-induced NF-ΚB activation in H1299 and A293 cells (Fig. 1F ). Gossypin inhibited TNF-induced NF-κB activation in these epithelial cells, indicating that gossypin-induced suppression of NF-κ B activation is not cell type specific.
Gossypin also suppressed constitutive NF-κB activation:
Most tumor cells express constitutively active NF-κB 26 , although the mechanism of constitutive activation is not well understood. The cell lines BxPC3 (pancreatic cancer), U266 (multiple myeloma), and 253JBV (bladder cancer) are known to express constitutively active NF-κB. Treatment with gossypin suppressed constitutive NF-κB activation in these cells (Fig. 1G ).
Gossypin was a potent inhibitor of NF-κB activation:
We treated cells with various concentrations of TNF for 30 min, with or without gossypin, and then used EMSA to assess for NF-κB activation (Fig. 1H ). Gossypin abolished TNF-induced NF-κB activation, even when exposed to TNF at a concentration of 10 nmol/L.
Gossypin inhibits TNF-dependent IκBα degradation:
We next determined how gossypin inhibits TNF-induced NF-κB activation. Cells were exposed to gossypin for 2 h and then treated with TNF for different periods of time.
Nuclear extracts were then prepared and analyzed for NF-κB; cytoplasmic extracts were prepared and analyzed for IκBα. As shown in Fig. 2A , gossypin completely inhibited TNF-induced NF-ΚB activation. Gossypin also suppressed TNF-induced IκBα degradation, as determined by Western blot analysis (Fig. 2B ).
Gossypin inhibited TNF-dependent IκBα phosphorylation:
IκBα phosphorylation is needed for IκBα degradation; thus, we determined whether gossypin modulated IκBα phosphorylation. Because TNF-induced phosphorylation of IκBα leads to its rapid degradation, we blocked IκBα degradation with the proteasome inhibitor N-acetyl-Leu-Leu-norleucinal. We performed a Western blot analysis using an antibody that is specific for the serine-phosphorylated form of IκBα and found that gossypin suppressed TNF-induced phosphorylation of IκBα (Fig. 2C ).
Gossypin inhibited TNF-induced IKK activation:
IKK is required for TNF-induced phosphorylation of IκBα and for the phosphorylation of p65 27 . Because gossypin inhibited the phosphorylation of IκBα, we determined its effects on TNF-induced IKK activation. Immune complex kinase assays showed that gossypin suppressed TNF-induced IKK activation (Fig. 2D ). Neither TNF nor gossypin affected the expression of IKK proteins.
Gossypin inhibited TNF-induced p65 nuclear translocation:
We performed an immunocytochemical analysis to determine whether gossypin modulates TNF-induced p65 nuclear translocation. Gossypin suppressed the TNFinduced nuclear translocation of p65 (Fig. 2E) .
Gossypin inhibited TNF-induced p65 phosphorylation:
p65 phosphorylation of is required for the transactivation of NF-κB. We used phosphospecific anti-p65 (Ser 536) antibody to determine whether gossypin modulates p65 phosphorylation. As shown in Fig. 2F and G, TNF induced p65 phosphorylation; this was substantially inhibited by gossypin. This finding was related to suppression of p65 nuclear translocation and was confirmed by an immunocytochemical analysis.
Gossypin suppressed TNF-induced NF-κB -dependent reporter gene expression:
Because DNA binding is not always related to NF-κB -dependent gene transcription 28 , we determined the effects of gossypin on TNF-induced reporter activity. Cells were transiently transfected with the NF-κB -regulated SEAP reporter construct, incubated with gossypin, and stimulated with TNF. TNF induced NF-κB reporter activity; this activity was substantially diminished by gossypin (Fig. 3A) . These results suggest that gossypin inhibits TNF-induced gene expression. In addition, DN-IκBα plasmid suppressed TNF-induced reporter activity, indicating its specificity.
Gossypin inhibited NF-κB activation induced by TNFR1, TRADD, TRAF2, NIK, and IKK:
TNF-induced NF-κB activation is mediated through sequential interaction of TNFR and TRADD, TRAF2, NIK, and IKK, resulting in phosphorylation of IκBα
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. We transiently transfected cells with the NF-κB -regulated SEAP reporter construct and TNFR1-, TRADD-, TRAF2-, NIK-, IKK-β-, or p65-expressing plasmids and treated them with gossypin and then monitored them for NF-κB -dependent SEAP expression. Gossypin suppressed NF-κB activation induced by TNFR1, TRADD, TRAF2, NIK, and IKK-β but not that induced by p65 (Fig. 3B) .
Gossypin inhibited TAK-1-induced NF-κB activation:
TNF-induced NF-κB activation may require the recruitment of TAK-1, an upstream kinase to IKK 30,31 . Thus, we determined whether gossypin inhibits this kinase. TAK-1 activated NF-κB activity, and gossypin inhibited TAK-1-and TAB-1-mediated NF-κB activation (Fig. 3C ). These results suggest that gossypin acts upstream of IKK.
Gossypin inhibited TNF-induced NF-κB-regulated antiapoptotic gene products:
NF-κB is key to the survival of tumor cells, as its activation induces the expression of antiapoptotic gene products. Because gossypin inhibited TNF-induced NF-κB activation, we hypothesized that it would also inhibit TNF-induced antiapoptotic gene products, such as survivin, Bcl-xL, c-FLIP, XIAP, Bcl-2, cIAP2, and TRAF-1, all known to be regulated by NF-κB 31-37 . The results of our Western blot analysis show that gossypin inhibited the expression of all these proteins (Fig. 4A ).
Gossypin inhibited TNF-induced expression of proliferative gene products:
NF-κB activation has been shown to regulate the expression of COX-2, cyclin D1, and cmyc 38-40 involved in the proliferation of various tumor cells. Therefore, we determined whether the expression of these gene products is modulated by gossypin. As shown in Fig. 4B , gossypin suppressed the TNF-induced expression of all these gene products.
Gossypin suppressed TNF-induced MMP-9 and VEGF expression:
MMP-9 involved in tumor cell invasion and metastasis, is regulated by NF-κB 41 . A
Western blot analysis showed that gossypin inhibited TNF-induced MMP-9 expression (Fig. 4C) .
VEGF is the most potent angiogenic factor, and recent studies have found that its expression is regulated by NF-κB 42 . Therefore, we determined the effect of gossypin on TNF-induced VEGF expression. TNF-induced VEGF and gossypin inhibited TNFinduced VEGF expression (Fig. 4C ).
Gossypin potentiated apoptosis induced by TNF and chemotherapeutic agents:
NF-κB activation can inhibit TNF and chemotherapeutic agents induced apoptosis through the expression of antiapoptotic gene products shown above [43] [44] [45] . Therefore, we determined whether gossypin enhances apoptosis induced by TNF and other cytotoxic agents. We used different methods to measure different aspects of apoptosis. We performed a Live/Dead assay, which measures cell membrane permeability, and found that gossypin upregulated TNF-induced cytotoxicity from 5% to 59% (Fig. 5A) . The 20 results of the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide method, which measures mitochondrial activity, showed that gossypin potentiates the cytotoxic activity of TNF (Fig. 5B ) and of taxol (Fig. 5C ). TUNEL and annexin staining also showed that TNF-induced apoptosis was enhanced by incubation with gossypin (Figs.
5D and E). We performed a caspase-3-activated PARP cleavage assay and found that gossypin had a dramatic effect on TNF-induced PARP cleavage (Fig. 5F) . The results of all these assays suggest that gossypin enhanced cytotoxicity by enhancing the apoptotic effects of TNF and taxol.
Gossypin suppressed TNF-induced invasion activity:
Matrix metalloproteinases (MMPs) have been found to provide critical assistance to tumor cells during metastasis. Because gossypin was found to suppress TNF-induced MMP-9 expression, we determined its effects on TNF-induced invasion. For this experiment, we seeded H1299 cells in the top chamber of a Matrigel invasion chamber in the absence of serum. Cells were incubated with TNF, with or without gossypin, for 24 h. As shown in Fig. 6A , gossypin suppressed TNF-induced cell invasion activity.
Gossypin inhibited RANKL-induced osteoclastogenesis:
RANKL was recently implicated as a major mediator of bone resorption 46 . Thus, agents that suppress RANKL signaling may inhibit bone resorption or osteoclastogenesis. To determine the effect of gossypin on osteoclastogenesis, we incubated RAW 264.7 cells with 5 µmol/mL gossypin in the presence of RANKL and allowed them to grow and differentiate into osteoclasts. Figures 6B and 6C illustrate that RANKL-induced osteoclast differentiation and gossypin substantially decreased it. A 5 µmol/mL concentration of gossypin was sufficient to reduce osteoclastogenesis by more than 65%.
Under these conditions, the cells remained fully viable (data not shown).
Whether gossypin also inhibits RANKL-osteoclastogenesis in primary bone marrow cells, was also examined. Figures 6D and 6E indicate that gossypin substantially decreased RANKL-induced osteoclast differentiation in these cells as well.
Effect of Gossypin on HUVEC Migration:
To examine the potential effect of gossypin on migration, we performed the Woundhealing/migration assay. The HUVECs migrated into the wounded area in response to VEGF stimulation and this migration was strongly inhibited by gossypin in a dosedependent manner over the range of 0.01-10µΜ ( Fig. 7 A and B) .
Gossypetin lacks the ability to suppress NF-κB activation:
We also examined the effect of gossypetin, an aglycone analogue of gossypin, on TNF induced NF-κB activation. The results showed that under the conditions gossypin completely suppressed TNF induced NF-κB inhibition, gossypetin had no effect (Fig. 7 C), thus indicating the importance of carbohydrate moiety.
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Discussion
The present study was aimed at evaluating the role of gossypin in NF-κB activation and NF-κB -regulated gene expression, apoptosis, invasion, and osteoclastogenesis.
Gossypin, but not gossypetin, inhibited NF-κB activation induced by different carcinogens and proinflammatory molecules and inhibited constitutive NF-κB expression. Gossypin inhibited NF-κB by suppressing TAK-1-mediated IKK activation, leading to the inhibition of IκBα phosphorylation and degradation, p65 phosphorylation and translocation, and NF-κB -mediated gene transcription. Gossypin also inhibited the NF-κB-regulated gene products involved in suppressing apoptosis, proliferation, invasion, and angiogenesis, leading to apoptosis potentiation induced by TNF and taxol. Gossypin's suppression of NF-κB activation was also associated with inhibition of TNF-induced invasion and RANKL-induced osteoclastogenesis. Gossypin also suppressed VEGF induced HUVEC migration.
To our knowledge, ours is the first study to demonstrate that gossypin can suppress NF-κB activation induced by inflammatory stimuli such as TNF, IL-1β, and LPS; prooxidants such as H 2 O 2 ; and carcinogens such as okadaic acid, tumor promoter, and cigarette smoke. Gossypin's suppression of these agents suggests that it acts at a step that is common to all these agents. We found that gossypin inhibited NF-κB activation by inhibiting IKK activation, which led to the suppression of IκBα phosphorylation, p65 phosphorylation, and nuclear translocation. The suppression of IKK by gossypin was found to result from the inhibition of upstream regulatory kinases of IKK such as TAK-1 31 . In the present study, we found that gossypin suppressed TAK-1-mediated NF-κB activation. However, whether suppression of NF-κB activation by other stimuli also occurs through inhibition of TAK-1 is unclear. Besides inducible NF-κ B activation, we found that gossypin also suppressed the constitutive activation of NF-κ B commonly seen in a wide variety of tumors [47] [48] [49] [50] [51] [52] [53] .
Gossypin has been shown to exhibit antioxidant activity 3 . It is possible that gossypin mediates its effects on NF-κB activation by quenching oxygen free radicals.
However, this is unlikely because most free radical quenchers are not efficient at blocking NF-κB activation 54 . Moreover, there are other reports that suggest reactive oxygen species not to play a role in NF-κB activation 55 . Our current studies, however, cannot rule out the suppression of NF-κB activation through the antioxidant effects of gossypin.
We found that the expression of several gene products involved in the proliferation of tumor cells was suppressed by gossypin. Three of these products, cyclin D1, c-myc and COX-2 are essential for cellular proliferation and survival [56] [57] [58] .
Expression of the c-myc oncoprotein prevents cell cycle arrest in response to growthinhibitory signals, differentiation stimuli, and mitogen withdrawal. Moreover, myc activation in quiescent cells is sufficient to induce cell cycle entry in the absence of growth factors. Cyclin D1 exercises powerful control over the mechanisms that regulate the mitotic cell cycle. Our results indicate that gossypin inhibits the TNF-induced expression of these two genes, suggesting that it is a potent inhibitor of the cell cycle.
The suppression of tumor cell proliferation by gossypin may therefore be linked to the inhibition of expression of these gene products. The expression of most antiapoptotic
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From gene products was also suppressed by this flavone. This activity is consistent with gossypin's potentiation of apoptosis induced by TNF and chemotherapeutic agents and suggests that gossypin may be clinically useful.
Our results showed that gossypin inhibited the MMP-9 expression and TNFinduced invasive activity of H1299 cells, suggesting that gossypin not only blocks primary tumor development but also malignant progression, as previously published 4 .
In our study, gossypin also substantially inhibited TNF-induced COX-2 expression.
We found that gossypin inhibited TNF-induced VEGF expression in vitro, further
showing that gossypin has antiangiogenic activity, as reported earlier in Dalton's lymphoma ascites (DLA)-induced solid tumor bearing animals 4 .
Osteoclastogenesis is a process of bone loss commonly associated with aging and cancer. RANKL has been shown to play a critical role in osteoclastogenesis. We found For personal use only. on September 14, 2017. by guest www.bloodjournal.org From 
